Eligo Bioscience is pioneering advancements in microbiome gene editing through its proprietary GEM (Gene Editing of the Microbiome) platform. This innovative technology allows for in vivo editing of the microbiome's gene repertoire, which is crucial given the significant role that the microbiome plays in human health and disease. The platform is designed to address the genetic causality of various diseases by enabling the precise removal, modification, or addition of bacterial genes. This capability is supported by a robust intellectual property portfolio, which includes over 25 patent families covering diverse applications of gene editing within the microbiome.

The company's approach leverages CRISPR technology to achieve highly specific elimination of disease-promoting genes, modification of bacterial genetic sequences, and the addition of therapeutic genes. Eligo's technology is notable for its versatility, as it can target any bacterial species and utilize various delivery systems. This breadth of application positions Eligo at the forefront of microbiome research and therapeutic development, with the potential to significantly impact treatment strategies across multiple therapeutic areas.

France

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

Eligo Bioscience

Company Details